Atomo Signs Agreement with Innovation Scientific
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Innovation Scientific will handle the development and clinical studies, while Atomo will manufacture the product and seek regulatory approval. The partnership aims to commercialize the rapid HIV test globally within a specified timeframe, enhancing Atomo's product portfolio. This agreement is considered strategically significant for Atomo, expected to contribute to revenue growth in the future.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Earlier from Atomo Diagnostics
- Update - Investor Webinar Presentation
- Notification of cessation of securities - AT1
- Investor Webinar Presentation
- 2026 Notice of Annual General Meeting
- FY26 Results and Strategy Presentation
Later from Atomo Diagnostics
- Quarterly Activities/Appendix 4C Cash Flow Report
- Q1 FY27 Results Presentation
- Change in substantial holding
- Chair's Address to Shareholders
- 2026 Annual General Meeting - MD & CEO's Address
Follow Atomo Diagnostics into a list and get an email when it puts out news.
Follow Atomo Diagnostics